IQVIA (NYSE:IQV) Given New $235.00 Price Target at Bank of America

IQVIA (NYSE:IQV) had its price target decreased by Bank of America from $255.00 to $235.00 in a research report released on Friday,Benzinga reports. Bank of America currently has a buy rating on the medical research company’s stock.

A number of other brokerages have also recently weighed in on IQV. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Evercore ISI decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Robert W. Baird dropped their price objective on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Morgan Stanley cut their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $256.19.

IQVIA Stock Down 0.7 %

NYSE IQV opened at $199.06 on Friday. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a market capitalization of $36.13 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 2.07 and a beta of 1.49. The stock’s 50 day moving average is $212.24 and its two-hundred day moving average is $224.23. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP bought a new stake in IQVIA in the 3rd quarter valued at approximately $27,000. Park Place Capital Corp bought a new stake in IQVIA during the 3rd quarter worth about $28,000. Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA during the 2nd quarter worth about $29,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the second quarter valued at about $32,000. Finally, Avior Wealth Management LLC raised its holdings in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.